Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
27 Luglio 2023 - 12:30PM
Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage
biopharmaceutical company developing a new class of
complement-based medicines for patients with classical
complement-mediated autoimmune, neurodegenerative and ophthalmic
disorders, today announced the appointment of Jamie Dananberg,
M.D., as chief medical officer.
“We are delighted to join forces with Jamie during this exciting
time for Annexon. He will add significant translational and
development expertise to our platform approach that has
demonstrated robust functional benefit across several disorders and
is well positioned to shift the treatment paradigm for
complement-mediated diseases,” said Douglas Love, president and
chief executive officer of Annexon.
“I am impressed with the data demonstrated to date by Annexon’s
upstream complement approach which has the potential to benefit
millions of patients impacted with classical complement-mediated
disorders,” said Dr. Dananberg. “With data supporting proof of
concept across multiple diseases, several advanced-stage programs
at key inflection points, additional data readouts on the horizon,
and an outstanding collection of experienced drug developers, it’s
an exciting time to join the organization and build upon the
tremendous work accomplished to date.”
Dr. Dananberg joins Annexon with more than 20 years of drug
development experience across a variety of therapeutic areas in the
pharmaceutical and biotechnology industries. Most recently, he
served as the chief medical officer for UNITY Biotechnology, where
as one of its earliest employees, he built the medical and broader
development organization. Prior to UNITY, Dr. Dananberg served as
executive vice president at Takeda Pharmaceuticals in several roles
including head, cardiovascular and metabolism therapeutic area, and
as the head of both the therapeutic areas group and
experimental/translational medicine. Before joining Takeda, he
spent 16 years at Eli Lilly & Co. where he brought more than
100 programs from discovery to development, leading and supporting
efforts through all phases, including the launches of multiple
commercial products. Before joining Lilly, he practiced medicine in
endocrinology and metabolism and ran a basic science laboratory at
the University of Michigan. Dr. Dananberg received his B.S. and
M.D. degrees from Tufts University.
About AnnexonAnnexon (Nasdaq: ANNX) is a
clinical-stage biopharmaceutical company seeking to bring
game-changing medicines to patients with classical
complement-mediated diseases of the body, brain and eye. The
classical complement pathway within the immune system, when
overactivated, drives inflammation in a host of autoimmune,
neurodegenerative and ophthalmic diseases. Annexon is advancing a
new class of complement medicines targeting the early classical
cascade and all downstream pathway components that contribute to
disease, while selectively preserving the beneficial immune
functions of other complement pathways. Annexon is rigorously
developing a pipeline of diversified product candidates across
multiple mid- to late-stage clinical trials, with clinical data
anticipated throughout 2023 and beyond.
Contacts: Investors:Chelcie ListerTHRUST
Strategic Communicationschelcie@thrustsc.com
Media:Sheryl SeapyReal
Chemistry949-903-4750sseapy@realchemistry.com
Grafico Azioni Annexon (NASDAQ:ANNX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Annexon (NASDAQ:ANNX)
Storico
Da Giu 2023 a Giu 2024